I share those same concerns - I think that in biotech the rapid dilution that happens early with professional CEOs bought in early means that there is less interest in building long term value - so short term wins like these can be worth it to founders that expect to be promoted to chief visionary officers. That might be harsh but I have co cerns about the incentives at some of these firms